These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1198 related articles for article (PubMed ID: 6374238)

  • 1. Plasminogen activators in human malignant melanoma.
    Markus G; Kohga S; Camiolo SM; Madeja JM; Ambrus JL; Karakousis C
    J Natl Cancer Inst; 1984 Jun; 72(6):1213-22. PubMed ID: 6374238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
    Markus G; Camiolo SM; Kohga S; Madeja JM; Mittelman A
    Cancer Res; 1983 Nov; 43(11):5517-25. PubMed ID: 6193874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
    Camiolo SM; Markus G; Englander LS; Siuta MR; Hobika GH; Kohga S
    Cancer Res; 1984 Jan; 44(1):311-8. PubMed ID: 6197164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.
    Holmberg L; Kristoffersson AC; Lecander I; Wallén P; Astedt B
    Scand J Clin Lab Invest; 1982 Jun; 42(4):347-54. PubMed ID: 6753100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
    Kohga S; Harvey SR; Weaver RM; Markus G
    Cancer Res; 1985 Apr; 45(4):1787-96. PubMed ID: 3884145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
    de Vries TJ; Kitson JL; Silvers WK; Mintz B
    Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
    Wilson EL; Becker ML; Hoal EG; Dowdle EB
    Cancer Res; 1980 Mar; 40(3):933-8. PubMed ID: 7193517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells.
    Laug WE
    J Natl Cancer Inst; 1985 Aug; 75(2):345-52. PubMed ID: 3860687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
    Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
    Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological characterization of plasminogen activator activities in human tissues and body fluids.
    Rijken DC; Wijngaards G; Welbergen J
    J Lab Clin Med; 1981 Apr; 97(4):477-86. PubMed ID: 6782183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
    Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
    J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.
    Bykowska K; Rijken DC; Collen D
    Thromb Haemost; 1981 Oct; 46(3):642-4. PubMed ID: 7198301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
    Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor growth and metastases in malignant disease. A review.
    Kwaan HC
    J Med; 1988; 19(3-4):179-91. PubMed ID: 3141546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo.
    Collen D; Rijken DC; Van Damme J; Billiau A
    Thromb Haemost; 1982 Dec; 48(3):294-6. PubMed ID: 6891842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
    Waghray A; Webber MM
    Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.